Finch Therapeutics Group Inc
NASDAQ:FNCH
Income Statement
Earnings Waterfall
Finch Therapeutics Group Inc
Revenue
|
107k
USD
|
Operating Expenses
|
-34.1m
USD
|
Operating Income
|
-34m
USD
|
Other Expenses
|
-40.8m
USD
|
Net Income
|
-74.8m
USD
|
Income Statement
Finch Therapeutics Group Inc
Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||||||
Revenue |
8
N/A
|
9
+23%
|
10
+5%
|
20
+96%
|
19
-5%
|
15
-17%
|
13
-16%
|
2
-87%
|
1
-48%
|
1
-28%
|
0
-58%
|
0
-54%
|
0
-11%
|
|
Gross Profit | ||||||||||||||
Cost of Revenue |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Gross Profit |
8
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
Operating Income | ||||||||||||||
Operating Expenses |
(47)
|
(55)
|
(64)
|
(74)
|
(79)
|
(84)
|
(88)
|
(88)
|
(96)
|
(88)
|
(75)
|
(57)
|
(34)
|
|
Selling, General & Administrative |
(14)
|
(16)
|
(20)
|
(23)
|
(21)
|
(26)
|
(28)
|
(32)
|
(38)
|
(38)
|
(39)
|
(33)
|
(27)
|
|
Research & Development |
(33)
|
(39)
|
(45)
|
(51)
|
(57)
|
(60)
|
(60)
|
(56)
|
(58)
|
(49)
|
(36)
|
(24)
|
(7)
|
|
Other Operating Expenses |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Operating Income |
(39)
N/A
|
(46)
-15%
|
(54)
-19%
|
(54)
+0%
|
(60)
-11%
|
(69)
-15%
|
(75)
-10%
|
(87)
-15%
|
(95)
-10%
|
(87)
+8%
|
(74)
+15%
|
(57)
+24%
|
(34)
+40%
|
|
Pre-Tax Income | ||||||||||||||
Interest Income Expense |
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
0
|
0
|
1
|
1
|
2
|
2
|
|
Non-Reccuring Items |
0
|
0
|
2
|
2
|
2
|
0
|
(1)
|
(20)
|
(20)
|
(71)
|
(70)
|
(51)
|
(50)
|
|
Gain/Loss on Disposition of Assets |
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
1
|
1
|
1
|
|
Total Other Income |
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
0
|
1
|
2
|
3
|
4
|
4
|
|
Pre-Tax Income |
(39)
N/A
|
(45)
-15%
|
(52)
-15%
|
(52)
+0%
|
(58)
-11%
|
(69)
-18%
|
(76)
-11%
|
(107)
-40%
|
(115)
-7%
|
(156)
-36%
|
(140)
+10%
|
(102)
+27%
|
(78)
+23%
|
|
Net Income | ||||||||||||||
Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
3
|
3
|
3
|
3
|
|
Income from Continuing Operations |
(39)
|
(45)
|
(52)
|
(52)
|
(58)
|
(69)
|
(76)
|
(107)
|
(115)
|
(152)
|
(137)
|
(99)
|
(75)
|
|
Net Income (Common) |
(39)
N/A
|
(45)
-15%
|
(52)
-15%
|
(52)
+0%
|
(58)
-11%
|
(69)
-18%
|
(76)
-11%
|
(107)
-40%
|
(115)
-7%
|
(152)
-33%
|
(137)
+10%
|
(99)
+28%
|
(75)
+24%
|
|
EPS (Diluted) |
-25.04
N/A
|
-28.92
-15%
|
-33.12
-15%
|
-33.03
+0%
|
-44.39
-34%
|
-43.51
+2%
|
-47.98
-10%
|
-67.1
-40%
|
-72.12
-7%
|
-95.26
-32%
|
-85.42
+10%
|
-61.7
+28%
|
-46.59
+24%
|